Targeted radiation therapy tested for Tough-to-Treat prostate cancer
NCT ID NCT05670106
Summary
This study tested a new type of targeted radiation therapy for Chinese men with advanced prostate cancer that has spread and stopped responding to standard hormone and chemotherapy treatments. The treatment uses a radioactive drug that seeks out and delivers radiation directly to prostate cancer cells. Researchers measured how well the treatment shrank tumors, controlled the disease, and how safe it was for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Guangzhou, Guangdong, 510120, China
-
Novartis Investigative Site
Zhengzhou, Henan, 450003, China
-
Novartis Investigative Site
Zhengzhou, Henan, 450008, China
-
Novartis Investigative Site
Wuhan, Hubei, 430022, China
-
Novartis Investigative Site
Nanjing, Jiangsu, 210006, China
-
Novartis Investigative Site
Nanjing, Jiangsu, 210029, China
-
Novartis Investigative Site
Xian, Shanxi, 710032, China
-
Novartis Investigative Site
Xian, Shanxi, 710061, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Beijing, 100034, China
-
Novartis Investigative Site
Beijing, 100036, China
-
Novartis Investigative Site
Beijing, 100730, China
-
Novartis Investigative Site
Guangzhou, 510060, China
-
Novartis Investigative Site
Shanghai, 200025, China
-
Novartis Investigative Site
Shanghai, 200032, China
-
Novartis Investigative Site
Shanghai, 200080, China
-
Novartis Investigative Site
Tianjin, 300300, China
Conditions
Explore the condition pages connected to this study.